GBP1 and ovarian cancer: Currently, although numerous molecular subtyping has been developed in ovarian cancer, such as IFNG, CD30, CXCL13, PRF1 GBP1, and ETV7 CTLA-4, they provided limited prognostic information or are not validated in the clinical samples [34–36].